Especially, before the advent and breakthrough of the BCR-ABL inhibitor imatinib as therapy for chronic myeloid leukemia (CML), IFNα was the treatment of choice for patients not suitable for bone marrow transplantation. The gene discussed is IFNA1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.